Steven M Horwitz1. 1. Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA. horwitzs@mskcc.org
Abstract
PURPOSE OF REVIEW: Peripheral T-cell lymphomas are an uncommon and heterogeneous group of non-Hodgkin's lymphomas that are noted for their particularly poor prognosis. Their rarity has resulted in few data being available to allow formulation of optimal treatment approaches. There remains no widely accepted standard therapy. A new and increasing interest in studying these lymphomas is leading to advances in our understanding, which is widening options for management. RECENT FINDINGS: Historically, peripheral T-cell lymphomas were treated with strategies borrowed from management of aggressive B-cell lymphomas. Investigators have recognized the inadequacy of these approaches, and we are beginning to receive results, often preliminary, of studies specifically designed to evaluate T-cell lymphomas. These range from transplantation approaches, to better prognostic schemes and to attempts at molecular characterization, and new drugs are being developed specifically for their activity against T-cell lymphomas. SUMMARY: Research in T-cell lymphomas is still mainly preliminary and studies tend to be small. Nonetheless, our understanding of these disorders is increasing, and data on new and hopefully better approaches are emerging.
PURPOSE OF REVIEW: Peripheral T-cell lymphomas are an uncommon and heterogeneous group of non-Hodgkin's lymphomas that are noted for their particularly poor prognosis. Their rarity has resulted in few data being available to allow formulation of optimal treatment approaches. There remains no widely accepted standard therapy. A new and increasing interest in studying these lymphomas is leading to advances in our understanding, which is widening options for management. RECENT FINDINGS: Historically, peripheral T-cell lymphomas were treated with strategies borrowed from management of aggressive B-cell lymphomas. Investigators have recognized the inadequacy of these approaches, and we are beginning to receive results, often preliminary, of studies specifically designed to evaluate T-cell lymphomas. These range from transplantation approaches, to better prognostic schemes and to attempts at molecular characterization, and new drugs are being developed specifically for their activity against T-cell lymphomas. SUMMARY: Research in T-cell lymphomas is still mainly preliminary and studies tend to be small. Nonetheless, our understanding of these disorders is increasing, and data on new and hopefully better approaches are emerging.
Authors: Owen A O'Connor; Barbara Pro; Lauren Pinter-Brown; Nancy Bartlett; Leslie Popplewell; Bertrand Coiffier; Mary Jo Lechowicz; Kerry J Savage; Andrei R Shustov; Christian Gisselbrecht; Eric Jacobsen; Pier Luigi Zinzani; Richard Furman; Andre Goy; Corinne Haioun; Michael Crump; Jasmine M Zain; Eric Hsi; Adam Boyd; Steven Horwitz Journal: J Clin Oncol Date: 2011-01-18 Impact factor: 44.544
Authors: S Horwitz; B Coiffier; F Foss; H M Prince; L Sokol; M Greenwood; D Caballero; F Morschhauser; L Pinter-Brown; S P Iyer; A Shustov; J Nichols; J Balser; B Balser; B Pro Journal: Ann Oncol Date: 2015-01-20 Impact factor: 32.976
Authors: Bertrand Coiffier; Barbara Pro; H Miles Prince; Francine Foss; Lubomir Sokol; Matthew Greenwood; Dolores Caballero; Franck Morschhauser; Martin Wilhelm; Lauren Pinter-Brown; Swaminathan Padmanabhan Iyer; Andrei Shustov; Tina Nielsen; Jean Nichols; Julie Wolfson; Barbara Balser; Steven Horwitz Journal: J Hematol Oncol Date: 2014-01-23 Impact factor: 17.388
Authors: Francine Foss; Bertrand Coiffier; Steven Horwitz; Barbara Pro; H Miles Prince; Lubomir Sokol; Matthew Greenwood; Adam Lerner; Dolores Caballero; Eugeniusz Baran; Ellen Kim; Jean Nichols; Barbara Balser; Julie Wolfson; Sean Whittaker Journal: Biomark Res Date: 2014-09-08
Authors: Francine Foss; Barbara Pro; H Miles Prince; Lubomir Sokol; Dolores Caballero; Steven Horwitz; Bertrand Coiffier Journal: Cancer Med Date: 2016-12-16 Impact factor: 4.452